Get started
Author

Shino Kuramoto

Observed names: 蔵本 詩乃, 蔵本詩乃
ORCID: 0009-0002-5202-1439
Observed ORCID: 0009-0002-5202-1439
OpenAlex ID: A5110596767
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
2023 · Mikimasa Tanada, Minoru Tamiya, et al. · Journal of the American Chemical Society · 197
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets
2023 · Atsushi Ohta, Mikimasa Tanada, et al. · Journal of the American Chemical Society · 121
The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
2011 · Hiroshi Tanaka, Miyuki Yoshida, et al. · Clinical Cancer Research · 102
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
2011 · Jun Ohwada, Hirosato Ebiike, et al. · Bioorganic & Medicinal Chemistry Letters · 73
Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s
2003 · Shizuo Narimatsu, Chie Takemi, et al. · Chirality · 37
Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19
2004 · Hiroyuki Hichiya, Shino Kuramoto, et al. · Biochemical Pharmacology · 19
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display
2024 · Mirai Kage, Ryuji Hayashi, et al. · Bioorganic & Medicinal Chemistry · 15
Prediction of drug-induced QT interval prolongation in telemetered common marmosets
2008 · Mitsuyasu Tabo, Toshiko Hara, et al. · The Journal of Toxicological Sciences · 15
PDF
Angiogenesis inhibitors identified by cell-based high-throughput screening: Synthesis, structure–activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation
2012 · Kihito Hada, Atsushi Suda, et al. · Bioorganic & Medicinal Chemistry · 14
Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the Emax Model
2017 · Shino Kuramoto, Motohiro Kato, et al. · Drug Metabolism and Disposition · 13
PDF
Evaluation of Methods to Assess CYP3A Induction Risk in Clinical Practice Using in Vitro Induction Parameters
2021 · Haruka Tsutsui, Shino Kuramoto, et al. · Biological and Pharmaceutical Bulletin · 11
PDF
Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor
2022 · Toshiya Ito, Kazutomo Kinoshita, et al. · Journal of Medicinal Chemistry · 9
Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats
2014 · Takehito Isobe, Ryuichi Komatsu, et al. · The Journal of Toxicological Sciences · 9
PDF
Abstract 1654: Anti-tumor activity of orally-available cyclic peptide LUNA18 through direct RAS inhibition in RAS-altered tumors
2024 · Hitoshi Sase, Saki Michisaka, et al. · Cancer Research · 8
Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice
2019 · Haruka Tsutsui, Motohiro Kato, et al. · Xenobiotica · 5
PDF
Impacts of anti-drug antibodies on pharmacokinetic and pharmacodynamic actions of cell-permeable middle molecule peptide drug
2025 · Mengxuan Gao, Ryota Saito, et al. · Journal of Pharmacology and Experimental Therapeutics · 4
Antitumor Activity of Orally Available Cyclic Peptide LUNA18 through Direct Pan-RAS Inhibition across Diverse RAS Genetic Alterations
2026 · Hitoshi Sase, Saki Michisaka, et al. · Molecular Cancer Therapeutics · 3
Abstract 1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation
2024 · Saki Michisaka, Hitoshi Sase, et al. · Cancer Research · 3
Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes
2019 · Chihiro Endo-Tsukude, Motohiro Kato, et al. · Drug Metabolism and Pharmacokinetics · 3
Free fraction comparison method for a highly protein binding compound by dynamic analysis in bi-directional dialysis
2025 · Fumihiko Igarashi, Fumiyo Matsuno, et al. · Drug Metabolism and Pharmacokinetics · 1
Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice
2024 · Haruka Tsutsui, Motohiro Kato, et al. · Drug Metabolism and Pharmacokinetics · 1
Exploiting Bridged Conformations for Precise Molecular Recognition in the Design of KRAS-Selective, Orally Available Macrocyclic Peptides
2026 · Mirai Kage, Hatsuo Kawada, et al. · Journal of the American Chemical Society
Abstract 5980: AUBE00: A novel cyclic peptide pan-KRAS inhibitor targeting KRAS-activated cancers including KRAS-mutant cancers and wild-type colorectal cancer
2026 · Kana Takei, Mayuki Ueda, et al. · Cancer Research
Abstract 5138: Chemical optimization of an orally bioavailable macrocyclic peptide KRAS inhibitors that achieve KRAS selectivity by recognizing a single amino acid difference
2026 · Mirai Kage, Hatsuo Kawada, et al. · Cancer Research
Impacts of anti-drug antibodies on pharmacokinetic and pharmacodynamic actions of cell-permeable middle molecule peptide drug
2025 · Mengxuan Gao, Ryota Saito, et al. · Drug Metabolism and Pharmacokinetics
Works count: 36
Citation count: 663
H-index: 11
I10-index: 11
Year
Topic
Type